NAS:ATAI (Germany)
Business Description
ATAI Life Sciences NV
Compare
Compare
Traded in other countries / regions
9VC.Germany
•
ATAI.Mexico
•
ATAI.USA
Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 504.82 | |||||
| Equity-to-Asset | 0.89 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 9.44 | |||||
| Beneish M-Score | 111.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.09 | |||||
| 9-Day RSI | 34.11 | |||||
| 14-Day RSI | 35.77 | |||||
| 6-1 Month Momentum % | -11.59 | |||||
| 12-1 Month Momentum % | -69.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.74 | |||||
| Quick Ratio | 14.74 | |||||
| Cash Ratio | 14.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -21085.89 | |||||
| Net Margin % | -29057.36 | |||||
| ROE % | -49.3 | |||||
| ROA % | -45.28 | |||||
| ROIC % | -352.26 | |||||
| ROC (Joel Greenblatt) % | -63890.81 | |||||
| ROCE % | -34.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 662 | |||||
| PB Ratio | 1.72 | |||||
| Price-to-Tangible-Book | 1.72 | |||||
| EV-to-EBIT | -1.69 | |||||
| EV-to-Forward-EBIT | -0.99 | |||||
| EV-to-EBITDA | -1.69 | |||||
| EV-to-Forward-EBITDA | -1 | |||||
| EV-to-Revenue | 356.13 | |||||
| EV-to-Forward-Revenue | 2250.39 | |||||
| EV-to-FCF | -2.48 | |||||
| Price-to-Net-Current-Asset-Value | 1.87 | |||||
| Price-to-Net-Cash | 1.95 | |||||
| Earnings Yield (Greenblatt) % | -59.17 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATAI
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.666 | ||
| EPS (TTM) ($) | -1.31 | ||
| Beta | 0 | ||
| Volatility % | 54.35 | ||
| 14-Day RSI | 35.77 | ||
| 14-Day ATR ($) | 0.258205 | ||
| 20-Day SMA ($) | 3.781 | ||
| 12-1 Month Momentum % | -69.57 | ||
| 52-Week Range ($) | 2.95 - 17.81 | ||
| Shares Outstanding (Mil) | 165.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
ATAI Life Sciences NV Analysis
Share your researchHeadlines
See More
No news.